speb/financial-data huggingface dataset:
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 153900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.27
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 3209100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — +Operating Expense: 3258900000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 805700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — +Total Revenue: 14825100000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 3648100000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1281500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1281500000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 1121600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 1121600000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 91672491.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 91648352.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Basic EPS: 20.03
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 4.55
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 614800000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -596500000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 368600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 368600000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 49300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 49300000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 2742200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 2742200000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -410300000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -8700000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Change In Payable: 27900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -319100000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -299900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -565500000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 7403700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 7403700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 27900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 27900000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 9333300000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2350700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Current Assets: 4165900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 4165900000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 36800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 36800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 36800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 36800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1695500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1695500000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 60400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 60400000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Depreciation: 436300000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 436300000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 436300000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 113400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 436300000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 113400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 91672491.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 91648352.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Diluted EPS: 20.03
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 4.55
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — EBIT: 2520400000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — EBIT: 565000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — EBITDA: 2956700000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — EBITDA: 678400000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — End Cash Position: 49300000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -463800000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1077900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -6100000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 3400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 3400000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 3672700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 3672700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Gross Profit: 5491800000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 1297400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Interest Expense: 60200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 14900000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 60200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 14900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -29200000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Interest Paid Cfo: -100000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 248300000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Inventory: 78600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 78600000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 7403700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 7403700000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -1776100000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 2035000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 2035000000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 331800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 331800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 331800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 331800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 269700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 269700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 417000000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 2460200000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 417000000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Interest Income: -60200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -14900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 11400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -60200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -14900000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -1439300000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Net PPE: 3672700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 3672700000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -596500000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 7400300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 7400300000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 203700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 203700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 2956700000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 678400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Normalized Income: 1836200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 417000000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 1674400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Operating Income: 2232900000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Operating Income: 491700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Operating Revenue: 14825100000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 3648100000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 122800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 122800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 220200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 220200000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 6487000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 6487000000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -246800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 36600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 36600000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 287500000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 73300000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 2822600000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 692300000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Properties: 3644800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 3644800000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 2692900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 2692900000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Payables: 1281500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Payables: 1281500000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Pretax Income: 2460200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 550100000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -596500000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 9333300000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 2350700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 436300000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 113400000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Share Issued: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 91673000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 7403700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 7403700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 7400300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 7400300000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Tax Provision: 624000000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 133100000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.24
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 100700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 100700000.00
INDRAMEDCO.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -669200000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Assets: 9913600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 9913600000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 7403700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 7403700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Debt: 368600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 368600000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 7403700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 7403700000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Total Expenses: 12592200000.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 3156400000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 2509900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2509900000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 5747700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 5747700000.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 814400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 814400000.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2026-03-31) — Working Capital: 2470400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 2470400000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — +Operating Expense: 3171903000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — +Total Revenue: 10387336000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 1759527000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 4547840000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -6914004000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 3073103000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Assets Held For Sale Current: 20095000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Available For Sale Securities: 114934000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 59086865.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Basic EPS: -4.28
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 116006000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 2686873000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Capital Expenditure: -184149000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Capital Lease Obligations: 5332000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 598058000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 214776000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 333676000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 101823000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 112953000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -528337000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: -405876000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 316814000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -261763000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -879164000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Changes In Cash: 141694000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Common Stock: 598058000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 6009723000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 103584000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 6291203000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Assets: 10753324000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 270000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Debt: 1046990000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 1047260000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 53882000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 3344653000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 53882000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Deferred Tax: -902000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Depreciation: 1310387000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 1310387000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 1310387000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 1310387000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 59086865.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Diluted EPS: -4.28
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: -21490000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — EBIT: 1039852000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — EBITDA: 2350239000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — End Cash Position: 257700000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: -1408769000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 1171308000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Fixed Assets Revaluation Reserve: 1964921000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Free Cash Flow: 1318592000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of Business: -106612000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: 136663000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 204059000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Goodwill: 351000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 10000000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Gross PPE: 13292856000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Gross Profit: 4096133000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Held To Maturity Securities: 175693000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Impairment Of Capital Assets: 71008000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Interest Expense: 914528000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 914528000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Interest Income: 5621000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 5621000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Interest Paid Cff: -1048651000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Interest Received Cfi: 5621000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Inventory: 4285003000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Invested Capital: 15534549000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: 47722000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Investment Properties: 27071000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 290627000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 560227000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 5062000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 8477836000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 8482898000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 0.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -360118000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Long Term Provisions: 170289000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 9470846000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Minority Interest: -1102000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Net Debt: 9310050000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: 37544000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income: -21490000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: -21490000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: -21490000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income Discontinuous Operations: 0.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: -21490000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: -21490000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 125324000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: -21490000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Intangibles Purchase And Sale: 0.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Interest Income: -949837000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: 171269000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -360118000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: -360118000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -949837000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Net PPE: 6378852000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -129168000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 5999723000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 1487000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Assets: 518983000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 170289000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 29090000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 2486902000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Normalized Income: 74174100.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: 1502741000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Operating Income: 924230000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Operating Revenue: 10387336000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 59086865.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Current Assets: 1000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Current Liabilities: 89033000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Equity Interest: 5411665000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 10000000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Inventories: -1000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: 879501000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Non Current Assets: -1000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: -1000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 139962000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 83115000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Payable: 128665000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Properties: 471326000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 531532000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 118900000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Other Special Charges: 65655000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Payables: 1888192000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 642773000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Pretax Income: 125324000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Provisionand Write Offof Assets: 0.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Purchase Of Intangibles: 0.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -184149000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 1199471000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 6291203000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 1310387000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 5158000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 5158000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Repayment Of Debt: -360118000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Research And Development: 327161000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: -780505000.00
INDSWFTLAB.NS cash_flow (annual, 2022-03-31) — Sale Of PPE: 54981000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 440007000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 644066000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Share Issued: 59086865.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Special Income Charges: -136663000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 6009723000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 5999723000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: -40998900.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Tax Provision: 146814000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.30
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 392404000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Assets: 18007947000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 14487559000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Debt: 9530158000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 6008621000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Total Expenses: 9463106000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 11999326000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 7254623000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 8654673000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 40930000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Total Unusual Items: -136663000.00
INDSWFTLAB.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: -136663000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 1487000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Work In Process: 1914225000.00
INDSWFTLAB.NS balance_sheet (annual, 2022-03-31) — Working Capital: 7408671000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — +Operating Expense: 2589263000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — +Total Revenue: 12073100000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 2039944000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 5053169000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -7458606000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 3073101000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 13951000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 127668000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 59086860.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Basic EPS: -4.28
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 214776000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 2696666000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -127707000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 5595000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 598058000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 181997000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 231541000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 101649000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 80348000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -101029000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -216099000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 170655000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -366785000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -513258000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -44061000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Common Stock: 598058000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 6819307000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 86637000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 7668630000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Assets: 11645170000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 270000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1089425000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1089695000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Deferred Taxes Liabilities: 122508000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 3710889000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 122508000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Deferred Tax: -2159000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Depreciation: 573622000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 573622000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 573622000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 573622000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 59086860.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Diluted EPS: -4.28
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — EBIT: 1729140000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — EBITDA: 2302762000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — End Cash Position: 170715000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -1856574000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 1281884000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Fixed Assets Revaluation Reserve: 1834100000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 1818489000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of Business: 0.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 10613000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 205155000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 13395645000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Gross Profit: 4404470000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Held To Maturity Securities: 175693000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Impairment Of Capital Assets: 10000000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Interest Expense: 863928000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 863928000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Interest Income: 58720000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 58720000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -1285230000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 5309000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Inventory: 4386032000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 15434728000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -133683000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Investment Properties: 24248000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 303361000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 557898000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 5325000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 7525996000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 7531321000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -459089000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 177888000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 9577568000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Net Debt: 8433424000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -30655000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income Discontinuous Operations: 0.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 475966000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 1131690000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 475966000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Interest Income: -862944000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -12733000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -459089000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -459089000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -862944000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -112255000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 1000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Net PPE: 5937039000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -126260000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 6819307000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 1234000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 298672000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 177888000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 32152000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 2579853000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Normalized Income: 669929700.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 1946196000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Operating Income: 1815207000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Operating Revenue: 12073100000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 59086865.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 1000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 102435000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: -19000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 776343000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: -2000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 1000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 9170000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 100272000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Payable: 153248000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Properties: 476876000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 973198000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 49544000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Other Special Charges: 267091000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Payables: 2315700000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 737411000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Pretax Income: 865212000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 0.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -127707000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 1211315000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 7668630000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 573622000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 7451000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 7451000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -459089000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: -293309000.00
INDSWFTLAB.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 1447000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 430613000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 635768000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Share Issued: 59086865.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Special Income Charges: -277091000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 6819307000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 6819307000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -83127300.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Tax Provision: 386903000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.30
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 249867000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Assets: 18240640000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 14345303000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Debt: 8621016000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 6819307000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Total Expenses: 10257893000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 11421333000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 6595470000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 7710444000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 57736000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 122508000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -277091000.00
INDSWFTLAB.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -277091000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1892833000.00
INDSWFTLAB.NS balance_sheet (annual, 2023-03-31) — Working Capital: 7934281000.00
INDSWFTLAB.NS income_statement (annual, 2024-03-31) — +Operating Expense: 4699904000.00
INDSWFTLAB.NS income_statement (annual, 2024-03-31) — +Total Revenue: 17091499000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 2928964000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 3129724000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -2982724000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 3826561000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -528470000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 0.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 604586000.00
INDSWFTLAB.NS income_statement (annual, 2024-03-31) — Average Dilution Earnings: 0.00
INDSWFTLAB.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 59086860.00
INDSWFTLAB.NS income_statement (annual, 2024-03-31) — Basic EPS: 91.18
INDSWFTLAB.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 344175000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1413751000.00
INDSWFTLAB.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -730104000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 2314000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 672116000.00
INDSWFTLAB.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 4778129000.00